Pemafibrate and Its Effects on Retinal Cells
Author Information
Author(s): Ohguro Hiroshi, Nishikiori Nami, Sato Tatsuya, Watanabe Megumi, Higashide Megumi, Furuhashi Masato
Primary Institution: Sapporo Medical University
Hypothesis
What are the pharmacological effects of pemafibrate on retinal pigment epithelium cells compared to another PPARĪ± agonist, GW7647?
Conclusion
Pemafibrate induces lower levels of ANGPTL4 expression in retinal cells compared to GW7647, which may reduce the risk of retinal ischemic diseases.
Supporting Evidence
- Pemafibrate and GW7647 had significantly different effects on cellular metabolic functions.
- ANGPTL4 was the only gene significantly upregulated by both drugs in all comparisons.
- Lower upregulation of ANGPTL4 by pemafibrate may minimize the risk for retinal ischemic diseases.
Takeaway
This study looks at how a drug called pemafibrate affects cells in the eye. It found that pemafibrate is better at keeping certain harmful proteins lower than another drug, which is good for eye health.
Methodology
The study used Seahorse cellular metabolic analysis and RNA sequencing on ARPE19 cells treated with pemafibrate and GW7647.
Potential Biases
Potential off-target effects of pemafibrate were not fully investigated.
Limitations
The study did not explore the mechanisms behind the different effects of pemafibrate and GW7647 on ANGPTL4 expression.
Participant Demographics
Human-derived ARPE19 cells were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website